MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
Adaptimmune Therapeutics plc Operating Expenses 2011-2026 | ADAP
Annual Operating Expenses Adaptimmune Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 141 M | 142 M | 118 M | 87 M | 33.8 M | 15 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | 15 M | 89.5 M |
Quarterly Operating Expenses Adaptimmune Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.7 M | - | - | - | 35.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.4 M | 19.7 M | 27.6 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.99 | 1.02 % | $ 508 M |  Britain |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.16 | 2.65 % | $ 1.71 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Certara
CERT
|
232 M | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.84 | 1.26 % | $ 116 M |  France |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Cellectar Biosciences
CLRB
|
15.3 M | $ 2.95 | 7.66 % | $ 36.1 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 95.2 | -0.08 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
49 M | $ 11.63 | -6.81 % | $ 592 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | $ 4.52 | 0.89 % | $ 841 M | Germany |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
555 M | $ 63.54 | 3.54 % | $ 7.12 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |